Sixteenth industry stakeholder platform on research and development support, European Medicines Agency, Amsterdam, the Netherlands, from 2 July 2026, 12:30 (CEST) to 2 July 2026, 17:30 (CEST)

Submitted by Anonymous (not verified) on 9 July 2026 - 11:03

Sixteenth industry stakeholder platform on research and development support, European Medicines Agency, Amsterdam, the Netherlands, from 2 July 2026, 12:30 (CEST) to 2 July 2026, 17:30 (CEST)

eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course (Bucharest) - October 2026, Hotel Capital Plaza Bucharest, from 29 October 2026, 08:00 (CET) to 30 October 2026, 12:00 (CET)

Submitted by Anonymous (not verified) on 8 July 2026 - 16:00

eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) training course (Bucharest) - October 2026, Hotel Capital Plaza Bucharest, from 29 October 2026, 08:00 (CET) to 30 October 2026, 12:00 (CET)

Human medicines European public assessment report (EPAR): Ebixa, memantine, Date of authorisation: 15/05/2002, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 8 July 2026 - 15:44

Human medicines European public assessment report (EPAR): Ebixa, memantine, Date of authorisation: 15/05/2002, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 8 July 2026 - 15:40

Human medicines European public assessment report (EPAR): Trazimera, trastuzumab, Date of authorisation: 26/07/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Wyost, denosumab, Date of authorisation: 17/05/2024, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 8 July 2026 - 15:35

Human medicines European public assessment report (EPAR): Wyost, denosumab, Date of authorisation: 17/05/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mepsevii, vestronidase alfa, Date of authorisation: 23/08/2018, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 8 July 2026 - 15:32

Human medicines European public assessment report (EPAR): Mepsevii, vestronidase alfa, Date of authorisation: 23/08/2018, Revision: 9, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness